Paul Koller

1.0k total citations
46 papers, 369 citations indexed

About

Paul Koller is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Paul Koller has authored 46 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 20 papers in Public Health, Environmental and Occupational Health and 15 papers in Genetics. Recurrent topics in Paul Koller's work include Acute Myeloid Leukemia Research (21 papers), Chronic Myeloid Leukemia Treatments (21 papers) and Acute Lymphoblastic Leukemia research (19 papers). Paul Koller is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Chronic Myeloid Leukemia Treatments (21 papers) and Acute Lymphoblastic Leukemia research (19 papers). Paul Koller collaborates with scholars based in United States, Taiwan and China. Paul Koller's co-authors include Jennifer L. Hsu, Xian Wen Sun, Mien‐Chie Hung, Jung-Mao Hsu, Weiya Xia, Yi Du, Qingqing Ding, Qiongzhu Dong, Hirohito Yamaguchi and Chunxiao Liu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Paul Koller

39 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Koller United States	9	163	117	100	72	56	46	369
Keiko Kagami Japan	11	80 0.5×	130 1.1×	129 1.3×	78 1.1×	61 1.1×	37	379
Angélique Brunot France	12	117 0.7×	112 1.0×	27 0.3×	52 0.7×	36 0.6×	29	346
Yizhuo Zhang China	14	135 0.8×	221 1.9×	183 1.8×	101 1.4×	67 1.2×	47	472
Ender Soydan Türkiye	8	140 0.9×	121 1.0×	181 1.8×	83 1.2×	40 0.7×	26	399
Marie Jaksch Sweden	12	134 0.8×	123 1.1×	207 2.1×	139 1.9×	58 1.0×	14	545
Jean Jacques Sotto France	6	57 0.3×	101 0.9×	108 1.1×	59 0.8×	72 1.3×	6	327
Cheol Won Suh South Korea	9	129 0.8×	43 0.4×	71 0.7×	45 0.6×	59 1.1×	29	275
Honghui Huang China	14	123 0.8×	183 1.6×	76 0.8×	63 0.9×	23 0.4×	37	471
Alissa Visram Canada	12	198 1.2×	158 1.4×	244 2.4×	76 1.1×	41 0.7×	57	403
Yi‐Fang Chang Taiwan	12	153 0.9×	136 1.2×	84 0.8×	115 1.6×	86 1.5×	33	402

Countries citing papers authored by Paul Koller

Since Specialization

Citations

This map shows the geographic impact of Paul Koller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Koller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Koller more than expected).

Fields of papers citing papers by Paul Koller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Koller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Koller. The network helps show where Paul Koller may publish in the future.

Co-authorship network of co-authors of Paul Koller

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Koller. A scholar is included among the top collaborators of Paul Koller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Koller. Paul Koller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kantarjian, Hagop M., Yifan Zhai, Vivian G. Oehler, et al.. (2025). Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research. Cancer. 131(8). e35832–e35832. 2 indexed citations

Nguyễn, Kim, Dat Ngo, Vaibhav Agrawal, et al.. (2025). The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B‐ ALL With High Disease Burden. American Journal of Hematology. 100(12). 2209–2219.

Agrawal, Vaibhav, et al.. (2025). The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025. Current Oncology Reports. 27(6). 748–760.

Maiti, Abhishek, Pierre Péterlin, Daniel Morillo, et al.. (2024). ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction. Blood. 144(Supplement 1). 2876–2876. 1 indexed citations

Ngo, Dat, Shanpeng Li, Joycelynne Palmer, et al.. (2024). Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib. Leukemia & lymphoma. 65(3). 372–377. 2 indexed citations

Zhang, Jianying, Vinod Pullarkat, Vaibhav Agrawal, et al.. (2024). Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer. British Journal of Haematology. 205(1). 158–165. 1 indexed citations

Atallah, Ehab, Michael J. Mauro, Koji Sasaki, et al.. (2024). Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. Future Oncology. 20(38). 3065–3075. 7 indexed citations

Atallah, Ehab, Moshe Levy, Paul Koller, et al.. (2024). Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI). Blood. 144(Supplement 1). 479–479. 3 indexed citations

Sun, Xian Wen, Wei‐Jan Wang, Ri‐Yao Yang, et al.. (2023). Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. International Journal of Biological Sciences. 19(14). 4644–4656. 8 indexed citations

10.

Ngo, Dat, Brian Lee, Ibrahim Aldoss, et al.. (2023). AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage. Clinical Lymphoma Myeloma & Leukemia. 23. S298–S299. 2 indexed citations

11.

Ngo, Dat, et al.. (2023). Cladribine, Cytarabine, and Etoposide-Based Regimens Are Safe and Tolerable In Relapsed and Refractory Acute Myeloid Leukemia Patients. Acta Haematologica. 146(6). 538–542. 2 indexed citations

12.

Koller, Paul, Natalia Baran, Karine G. Harutyunyan, et al.. (2023). PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. Journal for ImmunoTherapy of Cancer. 11(10). e006619–e006619. 4 indexed citations

13.

Ngo, Dat, et al.. (2022). A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant. Transplantation and Cellular Therapy. 28(7). 349–354. 8 indexed citations

14.

Ball, Brian, Paul Koller, & Vinod Pullarkat. (2022). Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia. Current Opinion in Oncology. 34(5). 531–539. 3 indexed citations

15.

Jonas, Brian A., Karen Yee, Paul Koller, et al.. (2022). Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202). Blood. 140(Supplement 1). 9076–9077. 2 indexed citations

16.

Zhao, Dandan, Le Xuan Truong Nguyen, Fang Chen, et al.. (2021). Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. Leukemia. 36(2). 492–506. 5 indexed citations

17.

Ball, Brian, Shukaib Arslan, Paul Koller, et al.. (2021). Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. Blood. 138(Supplement 1). 3430–3430. 1 indexed citations

18.

Aldoss, Ibrahim, Jianying Zhang, Matthew Mei, et al.. (2020). Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia. American Journal of Hematology. 95(10). 1193–1199. 27 indexed citations

19.

Li, Hui, Chia‐Wei Li, Xiaoqiang Li, et al.. (2019). MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 156(6). 1849–1861.e13. 154 indexed citations

20.

Anaya, Daniel A., Janice N. Cormier, Yan Xing, et al.. (2011). Development and Validation of a Novel Stratification Tool for Identifying Cancer Patients at Increased Risk of Surgical Site Infection. Annals of Surgery. 255(1). 134–139. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact